Revenue and Profit - Revenue for Q1 2025 was CNY 3,180,547,599.31, a decrease of 1.92% compared to CNY 3,242,814,513.73 in the same period last year[7] - Net profit attributable to shareholders increased by 4.75% to CNY 636,707,931.59 from CNY 607,823,809.46 year-on-year[7] - Basic earnings per share rose by 9.23% to CNY 0.71 from CNY 0.65 in the previous year[7] - The total operating revenue for the current period is RMB 3,180,547,599.31, a decrease of 1.92% from RMB 3,242,814,513.73 in the previous period[30] - The net profit for the current period is RMB 803,641,985.42, representing an increase of 12.24% compared to RMB 716,078,960.15 in the previous period[30] - The operating profit for the current period is RMB 958,924,963.25, up from RMB 848,887,058.48 in the previous period, indicating a growth of 12.93%[30] Cash Flow and Investments - The net cash flow from operating activities decreased by 21.59% to CNY 724,730,912.38 compared to CNY 924,248,920.31 in the same period last year[7] - Investment cash inflow increased significantly to RMB 32,290,697.41, a 434.99% increase compared to the previous year[17] - Investment cash outflow decreased to RMB 254,040,597.78, a reduction of 45.18% year-on-year[17] - Net cash generated from investment activities improved to -RMB 221,749,900.37, a 51.51% reduction in losses compared to the previous year[17] - The net increase in cash and cash equivalents was RMB 3,627,344.76, a 101.93% improvement from a net decrease of RMB 188,391,565.87 in the previous year[17] - The cash flow from foreign currency exchange losses increased significantly to -RMB 11,438,352.18, a 1,557.26% decline compared to the previous year[17] - The company has reduced bank loan repayments, contributing to the improved cash flow situation[17] - The net cash flow from investing activities was negative at RMB -221,749,900.37, an improvement from RMB -457,336,601.18 in the previous period[32] - The net cash flow from financing activities was negative at RMB -487,915,315.07, compared to RMB -654,613,688.15 previously, showing a reduction in cash outflow[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 24,485,271,838.40, reflecting a slight increase of 0.12% from CNY 24,455,825,697.18 at the end of the previous year[8] - The total liabilities decreased to RMB 9,109,970,328.17 from RMB 9,550,079,103.14, a reduction of approximately 4.62%[29] - The cash and cash equivalents at the end of the period are RMB 10,830,774,329.69, showing a marginal increase from RMB 10,827,146,984.92 at the beginning of the year[27] - The inventory at the end of the period is RMB 1,900,256,033.70, a decrease of 4.87% from RMB 1,997,642,296.29 at the beginning of the year[27] Shareholder Information - The total number of common shareholders at the end of the reporting period was 52,367, with 52,348 being A-share shareholders[19] - The largest shareholder, Hong Kong Central Clearing Limited, holds 33.66% of shares, totaling 306,769,189 shares[20] - The company repurchased a total of 9,425,955 A-shares, accounting for 1.03% of the total share capital, with a total expenditure of RMB 341,957,191.15[24] - The company also repurchased 7,245,300 H-shares, representing 0.80% of the total share capital, with a total expenditure of HKD 190,692,395.00[25] Other Financial Metrics - Other income increased by 55.27% to CNY 44,485,866.21, primarily due to an increase in government subsidies received[16] - The company reported a significant decrease of 84.84% in trading financial liabilities, down to CNY 1,227,675.21 from CNY 8,096,946.08, mainly due to changes in forward foreign exchange contracts[15] - The company’s inventory write-down provision increased, leading to a 55.10% rise in asset impairment losses to CNY -6,355,971.69 from CNY -4,097,945.69 in the previous year[16] - The company's retained earnings increased to RMB 12,398,087,110.19 from RMB 11,761,379,178.60, reflecting a growth of 5.43%[29] - The total comprehensive income for the period was RMB 790,563,380.41, an increase from RMB 693,127,170.79 in the previous period, representing a growth of approximately 14%[31] - The other comprehensive income attributable to the parent company's shareholders was RMB -12,213,875.83, an improvement from RMB -23,160,894.39 in the previous period[31] - The cash inflow from financing activities totaled RMB 630,140,000.00, down from RMB 721,939,862.90, indicating a decrease of approximately 12.7%[33] - The company reported a decrease in cash outflows for operating activities, totaling RMB 2,703,265,415.19, compared to RMB 2,584,514,895.68, reflecting an increase of about 4.6%[32] - Research and development expenses for the current period are RMB 216,076,782.61, down from RMB 238,173,559.46 in the previous period, a decrease of 9.25%[30]
丽珠医药(01513) - 2025 Q1 - 季度业绩